Astbury Conversation

Sponsors

MedImmune

MedImmune pioneers innovative research across key therapeutic areas including RIA, cardiovascular & metabolic disease, oncology, neuroscience, and more. We develop medicines for unmet medical needs worldwide. We’re an industry leader in personalized medicine – developing new products that may allow doctors to prescribe a specific, customized treatment for each patient’s individual needs. We are the global biologics research and development arm of our parent company AstraZeneca, a recognized global leader in biopharmaceutical research and development. By combining AstraZeneca’s worldwide presence with our distinct and unique culture, processes, and standards, we continue to solve global healthcare challenges, redefine science, deliver better medicines, and help people live longer, healthier lives.

UCB

UCB aspires to be the patient-centric global biopharma leader, making a difference to the lives of people living with severe diseases. UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Looking ahead, we have a solid platform for continuous growth through 2022 with our core products Cimzia®, Vimpat® and Neupro® and Keppra®, and we are preparing the launches of our next wave of potential medicines to help patients with epilepsy, lupus and osteoporosis. At the same time, we are very excited about the progress in our early pipeline. The key element of our evolution is to focus on the delivery of increased patient value. There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients. Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Although our discovery platform has been successfully applied to therapeutic targets addressing a variety of disease areas, our primary clinical area of focus is currently cancer.  In addition, we are expanding our capabilities and building expertise in the area of fragment-based drug discovery diseases of the CNS. For more information about Astex Pharmaceuticals, please visit http://www.astx.com. For more information about our parent company,  Otsuka Pharmaceutical, please visit http://www.otsuka.com/en/

CellLogo_WhiteBackground

Cell Press is a leading publisher of cutting-edge biomedical research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research.

BMC has an evolving portfolio of some 300 peer-reviewed journals, sharing discoveries from research communities in science, technology, engineering and medicine. In 1999 we made high quality research open to everyone who needed to access it – and in making the open access model sustainable, we changed the world of academic publishing.

Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, PeptiDream, Pfizer and Teva.

The Journal of Biological Chemistry welcomes high-quality science that seeks to elucidate the molecular and cellular basis of biological processes. Papers published in JBC can therefore fall under the umbrellas of not only biological chemistry, chemical biology, or biochemistry, but also allied disciplines such as biophysics, systems biology, RNA biology, immunology, microbiology, neurobiology, epigenetics, computational biology, ’omics, and many more. The outcome of our focus on papers that contribute novel and important mechanistic insights, rather than on a particular topic area, is that JBC is truly a melting pot for scientists across disciplines. In addition, JBC welcomes papers that describe methods that will help scientists push their biochemical inquiries forward and resources that will be of use to the research community.

JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft-matter physics to nano-optics, from surface chemistry to molecular biology and from cell biology to biomedicine. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.

A global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities of the UK.

Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences. Papers published by the journal represent important advances of significance to specialists within each field.

Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, New England Biolabs is now a recognized world leader in the discovery, development and commercialization of recombinant and native enzymes for genomic research.

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.

Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, and in microscopy, nano-analysis and industrial applications. In recent years, Bruker has also become a provider of high-performance systems for cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology, and for molecular pathology research.